Skip to main content

Table 6 Treatment response of patients with chronic ITP with IL-4 and IL-4Rα

From: The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP

  IL4 CC IL4 non-CC   IL4Rα QQ IL4Rα non-QQ  
N (%) N (%) P value OR 95% CI N (%) N (%) P value OR 95% CI
All treatment, no. of cases (%) 14 (82.4) 83 (76.1) 0.76 1.39 0.37–5.22 71 (80.7) 26 (68.4) 0.10 2.08 0.87–4.97
Second line treatment, no. of cases (%) 9 (52.9) 28 (25.7) 0.04 3.25 1.15–9.25 29 (33.0) 8 (21.1) 0.21 1.84 0.75–4.52
Response to all treatments
 CR, no. of cases (%) 9 (64.3) 59 (71.1) 0.75 0.73 0.22–2.41 50 (70.4) 18 (69.2) 1.00 1.06 0.40–2.81
 RR (CR+R), no. of cases (%) 13 (92.9) 79 (95.2) 0.55 0.66 0.68–6.36 68 (95.8) 24 (92.3) 0.61 1.89 0.30–12.00
Prednisolone therapy, no. of cases (%) 12 (70.6) 70 (64.2) 0.79 1.34 0.44–4.08 62 (70.5) 20 (52.6) 0.05 2.15 0.98–4.70
Response to prednisolone therapy
 CR, no. of cases (%) 5 (41.7) 40 (57.1) 0.36 0.54 0.16–1.85 34 (54.8) 11 (55.0) 1.00 0.99 0.36–2.74
 RR (CR+R), no. of cases (%) 10 (83.3) 64 (91.4) 0.33 0.47 0.08–2.65 56 (90.3) 18 (90.0) 1.00 1.04 0.19–5.60
Splenectomy, no. of cases (%) 5 (29.4) 14 (12.8) 0.14 2.83 0.87–9.24 15 (17.0) 4 (10.5) 0.43 1.75 0.54–5.66
Response to splenectomy
 CR, no. of cases (%) 4 (80.0) 7 (50.0) 0.34 4.00 0.35–45.38 7 (46.7) 4 (100) 0.10   
 RR (CR+R), no. of cases (%) 5 (100) 9 (64.3) 0.26    10 (66.7) 4 (100) 0.53   
Eradication of Helicobacter pylori, no. of cases (%) 7 (41.2) 36 (33.6) 0.59 1.38 0.49–3.93 33 (37.9) 10 (27.0) 0.24 1.65 0.71–3.84
Response to eradication of Helicobacter pylori
 CR, no. of cases (%) 4 (57.1) 16 (44.4) 0.69 1.67 0.33–8.55 15 (45.5) 5 (50.0) 1.00 0.83 0.20–3.44
Severe ITP, no. of cases (%) 5 (29.4) 19 (17.4) 0.32 1.97 0.62–6.26 19 (21.6) 5 (13.2) 0.33 1.82 0.62–5.29
Refractory ITP, no. of cases (%) 0 (0) 10 (9.2) 0.36    9 (10.2) 1 (2.6) 0.28 4.22 0.52–34.51
Corticosteroid-dependent, no. of cases (%) 5 (33.3) 32 (30.2) 0.77 1.16 0.37–3.66 28 (33.3) 9 (24.3) 0.39 1.56 0.65–3.74
  1. Second line treatment: Patients in need of second line, CR (complete response): platelet count of at least 100 × 109/L, R (response): platelet count between 30 and 100 × 109/L and at least double the baseline count, severe ITP: presence of bleeding symptoms at presentation sufficient to mandate treatment, or occurrence of new bleeding symptoms requiring additional therapeutic intervention with a different platelet-enhancing agent or an increased dose, refractory ITP: failure to achieve at least R or loss of R after splenectomy, loss of R: platelet count 30 × 109/L or a less than 2-fold increase in platelet count from baseline or the presence of bleeding, corticosteroid-dependence: the ongoing need for continuous corticosteroid administration or frequent courses of corticosteroids to maintain a platelet count at or above 30 × 109/L and/or to avoid bleeding.
  2. ITP immune thrombocytopenia, IFN interferon, IL interleukin, OR odds ratio, CI confidence interval, SD standard deviation